Pharmafile Logo

payer survey

- PMLiVE

AbbVie signs gene therapy deal in eye care

AbbVie and REGENXBIO have teamed up on RGX-314, a potential one-time gene therapy against two leading causes of blindness, wet AMD and diabetic retinopathy.

- PMLiVE

David Hunt launches independent agency The Considered

The team includes Professor Shafi Ahmed, Aurora Archer, Jane Kidd and CCO Pete Armstrong

Solving healthcare problems: What needs to change?

In this month’s PME, Tanya Goodyear, Director of Innovation and Transformation at Lucid Group, details Lucid’s approach to solving healthcare problems and reflects on the learnings we can draw from...

Lucid Group Communications Limited

- PMLiVE

Mastering oneself

What does it take to be a biomedical strategy expert?

David Youds, Barney Mayles, Resonant Group

RESONANT GROUP ACQUIRES PR BUSINESS

Affirms Resonant’s mission to enable effective engagement in health

Bedrock Healthcare Communications

Biogen Idec building

Embattled Biogen talks up Aduhelm

Biogen CEO admitted the company was experiencing “near-term challenges” after the controversial approval of Alzheimer’s drug, Aduhelm

- PMLiVE

Green light for Amgen’s KRAS inhibitor in the UK

Lumakras – known as Lumykras in the UK – will be available to 600 lung cancer patients in England through an early access scheme.

- PMLiVE

Results for the inaugural QiC Dermatology Awards 2021 in association with Dermatology in practice announced!

The awards took place at the Reading office of the QiC Dermatology Awards sponsor, Sanofi Genzyme

Roche Basel Switzerland

Roche expands infectious disease test portfolio

PCR test specialist TIB Molbiol will join Roche to bolster its molecular diagnostics solutions for infectious diseases

Roche Basel Switzerland

Roche expands infectious disease test portfolio

PCR test specialist TIB Molbiol will join Roche to bolster its molecular diagnostics solutions for infectious diseases

- PMLiVE

Boehringer Ingelheim to boost antibody discovery with partner Twist

The biotech company will use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links